Vertex Pharmaceuticals

VRTX(Vertex Pharmaceuticals)

$511.810%

VRTX(Vertex Pharmaceuticals) Price Prediction Summary

AI-Generated
As of September 17, 2026, VRTX is currently showing short-term bearish conditions. The daily technical picture is weighted to the downside: bearish moving-average alignment, negative MACD, and weak RSI all point toward continued selling pressure. Key uncertainty remains around whether the SMA50 at ~510 can act as a floor or will be decisively broken. Watch the 510–515 support zone closely; a hold here might allow for relief, but any breakdown would target the 200-day MA near 470. RSI recovery above 50 and MACD positive cross would be required to signal a meaningful reversal.
Technical Indicators
Short-Term Bearish

Moving averages in bearish alignment; MACD negative; RSI neutral-to-weak.

Key Trading Levels

How Gate Predicts VRTX(Vertex Pharmaceuticals) Price

Multi-Source Data Collection

Three independent data sources—technical indicators, market sentiment, and market structure signals—are integrated in real time, covering price behavior, trader behavior, and supply-demand dynamics, ensuring the analysis does not rely on a single dimension.

Independent Analysis by Dimension

Technical indicators are used to identify trends and structural positions, market sentiment is used to assess risk appetite, and market structure signals are used to identify supply-demand and positioning changes. Each dimension independently generates signals within its most appropriate time frame.

Cross-Validation of Composite Signals

When signals across multiple dimensions align, confidence in the assessment increases; when signals diverge, it indicates a transitional or consolidation phase, helping to avoid being misled by a single indicator.

Technical Indicators

AI-GeneratedAs of September 17, 2026, **VRTX technical analysis** shows a corrective setup across the daily timeframe. The moving average structure is decidedly bearish: SMA20 at 536.02 is trading below SMA50 at 510.33, which sits below SMA200 at 469.73, confirming a downtrend with resistance overhead. MACD is negative at −0.1588 and flashing a sell signal, indicating continued downside momentum without bullish crossover in sight. RSI14 sits at 44.25, nestled just below neutral, suggesting weak momentum but not yet oversold territory—room remains for further weakness. The VRTX price forecast hinges on whether price can hold above the SMA50 as dynamic support; a break below 510 would reinforce the bearish structure and potentially accelerate toward the 200-day MA. The near-term VRTX outlook remains challenged until a convincing RSI recovery above 50 and MACD reversal signal a change of character.
IndicatorValueSignal
Exponential Moving Average (10)522.7303
Sell
Exponential Moving Average (100)493.9929
Buy
Exponential Moving Average (20)525.7261
Sell
Exponential Moving Average (200)475.4005
Buy
Exponential Moving Average (30)522.6606
Sell
Exponential Moving Average (50)513.018
Buy
Hull Moving Average (9)512.1557
Buy
Ichimoku Base Line (9, 26, 52, 26)531.27
neutral
Moving Averages Summary
neutral
Simple Moving Average (10)524.784
Sell
Simple Moving Average (100)481.1091
Buy
Simple Moving Average (20)536.102
Sell
Simple Moving Average (200)469.7403
Buy
Simple Moving Average (30)529.9807
Sell
Simple Moving Average (50)510.3585
Buy
Volume Weighted Moving Average (20)537.2473
Sell
Average Directional Index (14)23.614
neutral
Awesome Oscillator-7.5652
neutral
Bull Bear Power-20.2186
Buy
Commodity Channel Index (20)-99.5862
neutral
MACD Level (12, 26)-0.028
Sell
Momentum (10)-40.41
Sell
Oscillators Summary
neutral
Relative Strength Index (14)45.3119
neutral
Stochastic %K (14, 3, 3)8.0774
neutral
Stochastic RSI Fast (3, 3, 14, 14)3.4245
neutral
Ultimate Oscillator (7, 14, 28)38.959
neutral
Williams Percent Range (14)-87.7235
Buy
Technical Summary
neutral

Market Sentiment

AI-GeneratedNo data yet
Analyst Rating
--
Options Put/Call Ratio
17.3100%
Implied Volatility (IV)
17.9355

Influencing Factors

Corporate Earnings and Profit Growth

Revenue, net profit, and forward guidance are the core factors affecting stock prices.

Industry Competition Landscape and Market Share

Changes in a company's competitiveness within the industry and its market share will impact its long-term valuation.

Overall Market Valuation and Interest Rate Environment

When interest rates rise or overall market valuations are elevated, individual stocks are more likely to experience pullbacks.

Institutional Funds and Market Sentiment

Large-scale institutional inflows or outflows, along with changes in market risk appetite, can amplify stock price volatility.

FAQ

What data is used to generate the VRTX(Vertex Pharmaceuticals) price prediction?

x

VRTX(Vertex Pharmaceuticals) price prediction is typically based on three types of data: technical indicators (e.g., RSI, MACD, moving averages), market sentiment (e.g., capital flows and derivatives data), and market structure signals (e.g., positioning and supply-demand changes). Multi-dimensional data is used to enhance the completeness of the analysis.

How do supply and demand affect the VRTX(Vertex Pharmaceuticals) price prediction?

x

How are technical indicators used in the VRTX(Vertex Pharmaceuticals) price prediction?

x

What role does market sentiment play in the VRTX(Vertex Pharmaceuticals) price prediction?

x

What common factors can influence the VRTX(Vertex Pharmaceuticals) price prediction?

x

How can price predictions be used to assess the current market state of VRTX(Vertex Pharmaceuticals)?

x

Disclaimer

Gate only provides trade execution services. Any information, reports, opinions, comments, or other materials obtained from Gate, its employees, Gate-provided analytical tools, or third-party research do not constitute investment advice and should not be relied upon for investment decisions. You agree to do your own research and verify external information sources before making any investment. You further agree that Gate shall not be held liable for any loss or damage (including but not limited to loss of profits) arising directly or indirectly from the use of or reliance on such information. Nothing contained in any reports shall be interpreted as an explicit or implied promise, guarantee, or indication of profit, nor does it guarantee that losses can be limited or avoided. Please also note that data related to traditional finance such as forex and CFDs (e.g., real-time prices) displayed on this page is sourced from third parties, is provided for reference only, and is offered on an "as-is" basis without any representations or warranties of any kind, express or implied. Any third-party website links provided are not under Gate's control. Gate assumes no responsibility for the reliability or accuracy of such third-party websites or their content. For further details, please refer to our User Agreement.

Risk Warning

Traditional finance such as forex and CFDs may experience significant price fluctuations. Past performance is not a reliable indicator of future results. The vast majority of retail client accounts incur losses when trading forex and CFDs. Please ensure you fully understand how forex and CFDs operate and assess whether you are able to bear the risk of substantial losses. Even with stop-loss orders, your losses may exceed your initial deposit. Therefore, you should not engage in speculative trading with funds you cannot afford to lose, and you should ensure you are fully aware of the risks involved. The information provided by Gate is general in nature and does not take into account your investment objectives, financial situation, or specific needs. The content and prices on this website must not be interpreted as personal investment advice. Please ensure you fully understand the risks involved and seek independent professional advice where necessary. Gate reserves the right to terminate services at its sole discretion at any time. Gate is not liable for any losses resulting from such termination, including losses caused by closing positions at unfavorable market prices or forced liquidation. For more information, please refer to our Risk Disclosure.